Drake Richard R, Schwegler E Ellen, Malik Gunjan, Diaz Jose, Block Timothy, Mehta Anand, Semmes O John
Center for Biomedical Proteomics, Virginia Prostate Center, and Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, 23507, USA.
Mol Cell Proteomics. 2006 Oct;5(10):1957-67. doi: 10.1074/mcp.M600176-MCP200. Epub 2006 Jun 7.
The application of mass spectrometry to identify disease biomarkers in clinical fluids like serum using high throughput protein expression profiling continues to evolve as technology development, clinical study design, and bioinformatics improve. Previous protein expression profiling studies have offered needed insight into issues of technical reproducibility, instrument calibration, sample preparation, study design, and supervised bioinformatic data analysis. In this overview, new strategies to increase the utility of protein expression profiling for clinical biomarker assay development are discussed with an emphasis on utilizing differential lectin-based glycoprotein capture and targeted immunoassays. The carbohydrate binding specificities of different lectins offer a biological affinity approach that complements existing mass spectrometer capabilities and retains automated throughput options. Specific examples using serum samples from prostate cancer and hepatocellular carcinoma subjects are provided along with suggested experimental strategies for integration of lectin-based methods into clinical fluid expression profiling strategies. Our example workflow incorporates the necessity of early validation in biomarker discovery using an immunoaffinity-based targeted analytical approach that integrates well with upstream discovery technologies.
随着技术发展、临床研究设计和生物信息学的进步,利用高通量蛋白质表达谱通过质谱法在血清等临床体液中鉴定疾病生物标志物的应用不断发展。先前的蛋白质表达谱研究为技术重现性、仪器校准、样品制备、研究设计和监督生物信息数据分析等问题提供了必要的见解。在本综述中,讨论了提高蛋白质表达谱在临床生物标志物检测开发中效用的新策略,重点是利用基于凝集素的差异糖蛋白捕获和靶向免疫测定。不同凝集素的碳水化合物结合特异性提供了一种生物亲和方法,可补充现有的质谱仪功能并保留自动化通量选项。提供了使用前列腺癌和肝细胞癌患者血清样本的具体示例,以及将基于凝集素的方法整合到临床体液表达谱策略中的建议实验策略。我们的示例工作流程纳入了在生物标志物发现中使用基于免疫亲和的靶向分析方法进行早期验证的必要性,该方法与上游发现技术很好地整合。